Alkem Labs' board has approved the merger of its wholly-owned subsidiary, Adroit Biomed, with itself.

This move aims to integrate business operations, enhance scale, optimize costs, and simplify the corporate structure.

Adroit Biomed, engaged in pharmaceuticals and nutraceuticals trading, reported ₹59.68 Cr revenue and ₹7.57 Cr net worth in FY25. Since it's a 100% subsidiary, no new shares will be issued, ensuring no change in Alkem Labs' shareholding pattern.

The merger is expected to unlock value and strengthen the combined entity, subject to necessary approvals.